review Open AccessTop 1% cited

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

Annals of the Rheumatic Diseases · 2017 · Vol. 76(6) · pp. 978–991

Désirée van der Heijde✉(Leiden University Medical Center)Sofía Ramiro(Leiden University Medical Center)Robert Landewé(Zuyderland Medisch Centrum)Xenofon Baraliakos(Rheumazentrum Ruhrgebiet)Filip Van den Bosch(Ghent University Hospital)Alexandre Sepriano(Leiden University Medical Center)Andrea Regel(Rheumazentrum Ruhrgebiet)Adrian Ciurea(University Hospital of Zurich)Hanne Dagfinrud(Diakonhjemmet Hospital)Maxime Dougados(Délégation Paris 5)F. van Gaalen(Leiden University Medical Center)Pál Géher(Semmelweis University)Irene van der Horst‐Bruinsma(Amsterdam UMC Location Vrije Universiteit Amsterdam)Robert D. Inman(University of Toronto)Merryn JongkeesUta Kiltz(Rheumazentrum Ruhrgebiet)Tore K Kvien(Diakonhjemmet Hospital)Pedro Machado(University College London)Helena Marzo‐Ortega(University of Leeds)Anna Moltó(Délégation Paris 5)Victoria Navarro‐CompánSalih Özgöçmen(Erciyes University)Fernando Pimentel‐Santos(University of Lisbon)John D. Reveille(The University of Texas Health Science Center at Houston)Martín Rudwaleit(Ghent University)Jochen Sieper(Charité - Universitätsmedizin Berlin)Percival D. Sampaio‐Barros(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)Dieter WiekJürgen Braun(Rheumazentrum Ruhrgebiet)

View via DOI Full-text PDF

Spondyloarthritis Studies and Treatments Psoriasis: Treatment and Pathogenesis Rheumatoid Arthritis Research and TherapiesMedicineAxial spondyloarthritisPhysical therapySacroiliitisAnkylosing spondylitisInternal medicine

MeSH terms

AnalgesicsAnti-Inflammatory Agents, Non-SteroidalGlucocorticoidsHumansTumor Necrosis Factor-alphaTreatment OutcomeAntirheumatic AgentsInterleukin-17SpondylarthritisDrug Substitution